oncnursingnews5h
Accelerated Approval Sought for RP1-Nivolumab Combo for Pretreated Melanoma
The FDA received a biologics license application for accelerated approval of RP1 plus nivolumab for advanced, pretreated ...
oncnursingnews3d
FDA Accepts New Drug Application to Darolutamide Plus ADP for mHSPC
The FDA accepted a supplemental new drug application to darolutamide plus androgen deprivation therapy for metastatic hormone ...
oncnursingnews3d
Sabrina Mikan, PhD, RN, ACNS-BC
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews3d
Sharon Kauffman, PhD, RN, CNE, NPD-BC, OCN
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews4d
Bernardo L. Rapoport, MD
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews4d
Donna L. Berry, PhD, RN, AOCN, FAAN
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews4d
FDA Fast Tracks ALE.P02 for CLDN1-Poisitive Solid Cancers
The FDA granted a fast track designation to ALE-P02 for patients with CLDN1-positive squamous solid tumors. The FDA granted ...
oncnursingnews4d
Rapid Taper Plays Role in Suspected Opioid Misuse in Patients With Cancer
Clinicians should consider a rapid taper approach for patients with cancer who exhibit repeated signs of opioid misuse, an ...
oncnursingnews5d
Eric Blackstone, MA, Sara L. Douglas, PhD, RN, Amy R. Lipson, PhD
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...